STAT+: A biotech turns to Apple Watch to study its Parkinson’s drug
Why it matters: Wearables in drug trials could revolutionize Parkinson's research, offering hope for faster, more effective treatments.
- A biotech company is utilizing Apple Watch for studying its Parkinson's drug, indicating a move towards digital health tools in clinical trials.
- The STAT Health Tech newsletter highlights this development alongside physician perspectives on AI and a drug giant's investment in AI chips, showcasing broader trends in health technology.
- Wearable technology is being adopted to collect richer, continuous data, which could offer deeper insights into drug performance outside traditional clinical settings.
A biotech company is leveraging Apple Watch technology to study its Parkinson's drug, marking a significant shift towards integrating consumer wearables into clinical research. This innovative approach aims to gather more comprehensive and real-world data on drug efficacy, potentially accelerating development for a debilitating disease.
